517O Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial
Paul DiSilvestro(Women & Infants Hospital of Rhode Island), K.N. Moore(Oklahoma State University Oklahoma City), Charlie Gourley(Edinburgh Cancer Research), Michael Friedländer(Prince of Wales Hospital), Andrew Martin(Clinica Universidad de Navarra), Alexandra Léary(Institut Gustave Roussy), Giovanni Scambia(Agostino Gemelli University Polyclinic), N. Colombo(European Institute of Oncology), Elizabeth Lowe(AstraZeneca (United States)), John McNamara(AstraZeneca (United Kingdom)), Gabe S. Sonke(Oncode Institute), C. Aghajanian(Memorial Sloan Kettering Cancer Center), Susana Banerjee(Royal Marsden NHS Foundation Trust), Ana Oaknin(Hebron University), Amit M. Oza(Ontario Institute for Cancer Research), Anne Floquet(Institut Bergonié), B-G. Kim(Samsung Medical Center), Cara Mathews(Brown University), W.H. Bradley(Froedtert Hospital), Alla Lisyanskaya(City Clinical Oncology Center)
Cited by 6
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial
|The Lancet|2014|1.8k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k